Trending...
- Yonkers Mayor Spano Calls On State University Of New York (SUNY) To Establish A New Westchester Community College Campus At Former Leake & Watts Property
- Rochester: Appointments Available for COVID-19 Testing
- Rochester: Youth Invited to Apply for Summer Employment Programs
NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: https://www.prnewswire.com/news-releases/#finan..." rel="nofollow external noopener">"SCPS") today announced the pricing of a $9 million follow-on public offering. The offering consists of 1,000,000 shares of common stock at a public offering price of $9.00 per share. The company has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the public offering price. The offering is expected to close on or about January 29, 2021, subject to customary closing conditions.
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
Scopus intends to use the proceeds of the offering principally for further development of the company's lead drug candidate, including in combination with checkpoint inhibitors.
More on Nyenta.com
The Benchmark Company, LLC acted as Sole Bookrunning Manager and Joseph Gunnar & Co., LLC acted as Co-Manager for the offering.
Greenberg Traurig, LLP is acting as counsel to the company. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting as counsel to the underwriters.
An offering statement relating to the shares of common stock was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021. The offering is being made only by means of an offering circular, copies of which may be obtained, when available, by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected]; or Joseph Gunnar & Co., LLC, Attention: Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600 or by email at [email protected] The offering circular is also available on the U.S. Securities and Exchange Commission website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
More on Nyenta.com
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.
Forward-Looking Statements
This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's offering circular filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.
Contact
Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: [email protected]
SOURCE Scopus BioPharma Inc.
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
Scopus intends to use the proceeds of the offering principally for further development of the company's lead drug candidate, including in combination with checkpoint inhibitors.
More on Nyenta.com
- New Voices Foundation to Hold $100,000 Virtual Pitch Competition for Women of Color Entrepreneurs
- Carole Demas. Sarah Rice and Ian Herman Together Again
- Identity Podcast The Importance of Black History
- Pandemic Compliance Services Provides Certified Pandemic Compliance Advisors And Covid-19 Compliance
- Meatless Farm Launches First Plant-Based Hot Dog That Tastes Like a Real Hot Dog
The Benchmark Company, LLC acted as Sole Bookrunning Manager and Joseph Gunnar & Co., LLC acted as Co-Manager for the offering.
Greenberg Traurig, LLP is acting as counsel to the company. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting as counsel to the underwriters.
An offering statement relating to the shares of common stock was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021. The offering is being made only by means of an offering circular, copies of which may be obtained, when available, by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected]; or Joseph Gunnar & Co., LLC, Attention: Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600 or by email at [email protected] The offering circular is also available on the U.S. Securities and Exchange Commission website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
More on Nyenta.com
- Sandline Global Fortifies World-Class Executive Team: Glenn Hopper Joins as Chief Financial Officer
- Ponos Industries Extends Tender Offer for up to 1,000,000 Shares of Common Stock of Visa Inc
- GBKSOFT reveals the benefits of Building Websites with PHP in 2021?
- JT Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Jianpu Technology, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- AdvisorSmith Finds the States Most and Least Uninsured for Health Insurance
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.
Forward-Looking Statements
This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company's offering circular filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.
Contact
Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: [email protected]
SOURCE Scopus BioPharma Inc.
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Sober St. Patrick's Day® 10th Anniversary To Broadcast On March 17, 4 PM EST
- The Neighborhood Show Coming To Rude Rangers TV
- Bronx DWI Lawyer Announces New Website
- Recording Artist "Cherne" Crystal Brown auditions for Sony Music, Atlantic Records and Capitol Records and it doesn't stop there
- TCDA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Tricida, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
- Mayor Spano Announces Release of the Yonkers Police Reform Committee Final Report
- Jennifer S. Wilkov Joins February Writing Industry Roundtable Discussion to Inspire and Educate 2021 Writers
- Mathew Knowles Announces IMPACT, His New Podcast Show on iHeartRadio
- Honorary Oscar-Winner Charles Burnett brings his award winning film on COVID-19 / Black Hollywood to the Prestigious Pan African 2021 Film Festival
- New Rochelle: Commercial Strong-Arm Robbery- Four Suspects Sought
- Ponos Industries Amends Previously Announced Tender Offer for up to 1,000,000 Shares of Common Stock of Exxon Mobil Corporation
- PRA Health Sciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PRA Health Sciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PRAH
- In a year of recession, Lantek closes 2020 with record sales figures and customer numbers
- Employers Switch their Focus to the Long Game; Swings in Local COVID-19 Cases no Longer Impact Demand for Office Space
- Construction Chemicals Market Insights, Key Players, Growth Drivers and Future Scope
- The Koedo Kawagoe Spring Festival Celebrates the Arrival of Springtime in Kawagoe, Japan
- VidMob Raises $50 Million Series C to Accelerate Broad Adoption of its Platform for Intelligent Creative
- Aaron's Energy: An Unexpected Journey Through Grief and the Afterlife With My Brilliant Son
- ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN
- INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Clover Health Investments, Corp.